Amarna Therapeutics Forms Strategic Partnership with NorthX Biologics to Advance Gene Therapy Development

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Smart Immune and CELLforCURE Partner to Scale SMART101 Production for Advanced Cell Therapy Trials

Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract  Development and Manufacturing Organization (CDMO) for Adv...

December 03, 2024 | Tuesday | News
Jasper Therapeutics Doses First Patient in Phase 1b/2a ETESIAN Study of Briquilimab for Allergic Asthma

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...

December 03, 2024 | Tuesday | News
Kelun-Biotech's Sacituzumab Tirumotecan (Sac-TMT) Gains Marketing Approval for Advanced TNBC in China

The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...

December 02, 2024 | Monday | News
Ascentage Pharma’s Olverembatinib Gains Expanded Inclusion in China’s 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...

November 29, 2024 | Friday | News
European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
Eisai and Biogen Launch LEQEMBI® for Early Alzheimer's Treatment in South Korea

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
Roche to Acquire Poseida Therapeutics in Strategic Move to Advance Off-the-Shelf CAR-T Cell Therapies

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida&r...

November 27, 2024 | Wednesday | News
SCG Cell Thearapy Presents Promising Phase 1 Data for SCG101, a First-in-Class HBV-Specific TCR-T Therapy

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associa...

November 25, 2024 | Monday | News
Kedrion Biopharma's Bolognana Facility FDA-Approved to Manufacture RYPLAZIM® for PLGD-1 Treatment

 Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in B...

November 22, 2024 | Friday | News
Avirmax Biopharma Doses First Patient in Phase I/IIa Trial of ABI-110, Pioneering Gene Therapy for Wet AMD and PCV

Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, announced that the first patient has been successfully dosed in the Phas...

November 22, 2024 | Friday | News
TrakCel’s OCELLOS Platform Powers Cell and Gene Therapy Rollout, Supporting Five of Seven New Products for 2024

  "TrakCel’s OCELLOS platform, tailored for cell and gene therapies, has been chosen to manage supply chains for five of the seven autologous...

November 20, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close